Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).

Francis Lévi,Michel Ducreux,Denis Smith,Mohamed Hebbar,Céline Lepère,C. Focan,Rosine Guimbaud,Pasquale F. Innominato,Carlos Carvalho,Salvatore Tumolo,Stéphanie Truant,Denis Castaing,Abdoulaye Karaboué,Valérie Boige,Mohamed Bouchahda,Philippe Rougier,René Adam

Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228).

2014

Francis Lévi
Michel Ducreux
Denis Smith
Mohamed Hebbar
Céline Lepère
C. Focan
Rosine Guimbaud
Pasquale F. Innominato
Carlos Carvalho
Salvatore Tumolo
Stéphanie Truant
Denis Castaing
Abdoulaye Karaboué
Valérie Boige
Mohamed Bouchahda
Philippe Rougier
René Adam

3589 Background: IV chemotherapy (chemo) downsizes LM-CRC in most pts. Yet less than 15% of those with previously unresectable LM and prior chemo undergo successful complete macroscopic LM resectio...

Keywords:

Cetuximab
Gastroenterology
Artery infusion
KRAS
Pathology
Colorectal cancer
Medicine
Internal medicine
previously treated
liver surgery
IV Chemotherapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations